Articles tagged with Schizophrenia
A study published in PLOS Medicine found that men who participate in sports or vigorous physical activity are less likely to suffer from osteoporotic fractures. The researchers analyzed data from over 2,000 men and found that those with higher levels of physical activity had a significantly lower risk of fractures. By taking exercise, ...
Researchers have identified a check and balance system for neuron activity managed by neuregulin-1, revealing new treatment targets for psychiatric diseases like schizophrenia and neurological disorders such as epilepsy. The findings also provide insights into the cognitive deficits associated with these conditions.
In a six-week study, Aripiprazole demonstrated significant improvement compared to placebo on the Positive and Negative Syndrome Scale (PANSS) Total Score. The study found that approximately 85% of patients completed the study, and both doses of Aripiprazole showed improvement compared to placebo.
The study found that adults taking adjunctive aripiprazole had a greater reduction in MADRS Total Score compared to placebo, indicating improved depressive symptoms. Common adverse events included akathisia, insomnia, and restlessness, with a lower discontinuation rate due to adverse events for aripiprazole.
A six-month study demonstrated that bifeprunox maintained stability and displayed a favorable weight and lipid profile compared to placebo in patients with schizophrenia. The treatment also showed promising results in reducing the risk of deterioration over time.
Researchers used metabolomics to analyze blood chemicals in patients with schizophrenia before and after treatment, revealing distinct chemical signatures that differ according to the medication used. The findings may lead to earlier diagnosis, better treatment planning, and a deeper understanding of the disease's causes and effects.
Researchers have demonstrated that malfunctioning of the DISC1 gene causes symptoms similar to those of schizophrenia and depression in mice. Antipsychotic and antidepressant drugs alleviated these symptoms, supporting the theory that the two disorders share common genetic mechanisms.
Researchers have pinpointed how different types of damage to the DISC1 gene can cause schizophrenia and major depression. The study, published in Neuron, provides further evidence that these illnesses are inherited and may help doctors tailor treatments.
UC Irvine researchers identified a new class of compounds that target nicotinic receptors in the brain, improving working memory and filtering sensory input. The findings suggest potential treatment possibilities for schizophrenia, ADHD, and Alzheimer's disease, offering a safer alternative to nicotine.
Researchers discover that genetic alterations in NRG1-erbB signaling contribute to psychiatric disorders, including schizophrenia. They find that blocking this signaling pathway leads to changes in brain structure and function, affecting the dopamine system and causing behavioral symptoms.
Researchers discovered a molecular mechanism that strengthens brain networks by closing ion channels, which may improve working memory and reduce distractibility in conditions like ADHD. This discovery has implications for developing drug therapies for normal aging and treating cognitive changes in schizophrenia and bipolar disorder.
Bifeprunox demonstrates a favorable weight and lipid profile, comparable to placebo, in patients with stable schizophrenia. The treatment also showed decreases in body weight and minor reductions in BMI in patients with acute exacerbations of schizophrenia.
A study led by Dr. Diana Perkins identified lower levels of microRNAs in the brains of adults with schizophrenia compared to healthy individuals. The research suggests that altered expression of microRNAs may be involved in the development of schizophrenia, potentially related to disordered synaptic plasticity.
Researchers at The Feinstein Institute for Medical Research have discovered a new gene that increases the risk of developing schizophrenia. The study, which analyzed over 500,000 genetic markers, found a significant link between a chromosomal region called PAR1 and the disease.
A new study challenges the World Health Organization's idea that schizophrenia is relatively more benign in developing societies. The research compares biological and cultural indicators of schizophrenia in urban, Western societies with data from Palau, which has one of the highest rates of schizophrenia diagnosis in the world.
Two new studies from the CATIE trial provide more insights into comparing treatment options and their impact on people with schizophrenia. The trials found that newer antipsychotic medications like quetiapine and olanzapine may be more effective than older medications, but patient responses varied significantly.
A new framework has been established to determine schizophrenia risk based on eye movement and attention focus. Researchers found that individuals with dilute forms of schizophrenia-like symptoms are at higher risk, even if they have never had the illness.
A recent MIT study reveals a genetic link between gene mutations and schizophrenia, focusing on the calcineurin system as a potential target for future treatments.
Researchers have identified a genetic variation associated with a mild form of schizophrenia, which also confers improved overall survival. The HOPA12pb gene variation affects dopamine-releasing neurons and may hold the key to developing new treatments for schizophrenia and other related illnesses.
A common gene variant is found to optimize brain function and improve thinking abilities, but also increases the risk of developing schizophrenia. The study suggests that this variant may have a paradoxical effect when combined with impaired prefrontal cortex function.
Research reveals genetic variation in the DARPP-32 gene linked to improved cognitive performance and increased risk of schizophrenia. The study's findings suggest a possible genetic connection between the protein and frontostriatal brain structure and function.
A study published in The American Journal of Human Genetics identifies the chitinase 3-like 1 gene as a potential risk factor for schizophrenia. Genetic variations in this gene were found to be associated with schizophrenia, suggesting that genes involved in biological response to adverse conditions may play a role in predisposition.
Research found that individuals with schizophrenia are more likely to have multiple chronic health conditions, including cardiovascular and neurological diseases. A third of those with schizophrenia had three or more physical health conditions, highlighting the need for integrated care.
A study found that monitoring grey matter density over time using brain scans could help early detection of individuals at risk for schizophrenia. The results showed a correlation between reduced grey matter density and increased risk of developing the condition.
A study found that schizophrenia patients respond equally well to older psychiatric drugs as newer, costlier alternatives. The NHS-funded trial revealed little benefit from switching to second-generation anti-psychotics despite their higher market share.
A new study suggests that older antipsychotic medication perphenazine is less expensive and equally effective as newer medications for treating schizophrenia. The study, funded by the National Institutes of Health, found that total monthly health costs were up to 30% lower for patients taking perphenazine compared to those taking secon...
Researchers have identified characteristic changes in cerebrospinal fluid that may serve as biomarkers for psychosis, including schizophrenia. These findings suggest a potential new approach to understanding and treating these conditions.
Researchers at USC have made significant discoveries in the fight against Alzheimer's disease. A study found that hormone replacement therapy may lower Alzheimer's risk by as much as 50 percent in younger women. Additionally, a new treatment approach for ALS and Parkinson's disease has shown promising results, with exercise interventio...
A study found that second-generation antipsychotic medications do not offer significant benefits compared to older first-generation antipsychotic drugs for patients with schizophrenia. The findings contradict the widely held perception that second-generation agents are safer and more effective.
An international team, led by UCLA's Roel Ophoff, is conducting a four-year study on schizophrenia that will analyze the human genome of approximately 850 Dutch patients and 750 control subjects to pinpoint related genes. This approach aims to separate false clues from true genetic variants associated with the disorder.
The survey reveals that caregivers experience devastating consequences, including relapse, hospitalization, and financial strain. Caregivers also emphasize the importance of effective medication and long-term care to maintain their loved ones' overall well-being.
A new five-year study will determine whether biweekly physician visits and injectable drugs can improve medication compliance among schizophrenia patients. Researchers are comparing the effectiveness of injectable risperidone microspheres to standard oral antipsychotics.
A new risk factor for schizophrenia has been identified by UCLA scientists, with infants having a specific immune gene that closely resembles their mothers' being more likely to develop the disease. The study suggests that this genetic match may increase fetal susceptibility to schizophrenia, particularly in females.
A Wake Forest University research team is analyzing brain changes in individuals with schizophrenia and bipolar disorder to better understand the diseases. They are comparing post-mortem brain tissue with normal tissue, focusing on the temporal lobe's structures involved in learning and memory.
Researchers explore the connection between schizophrenia and an increased risk of developing type 2 diabetes. They aim to identify patients at high risk and develop more effective treatment plans.
Researchers found that children exposed to polychlorinated biphenyls (PCBs) receive lower antibody protection after vaccinations. The study suggests that reducing exposure to chemicals that harm immune systems is crucial for young children.
A new study found that variations of the OLIG2 gene are strongly associated with schizophrenia. The gene plays a crucial role in myelin production and is coordinated with other genes involved in myelination and schizophrenia development. This causal link may help researchers develop new therapeutic targets for the debilitating illness.
Research suggests that folate deficiency during pregnancy can cause genetic mutations leading to schizophrenia, challenging the conventional wisdom on psychiatric disorders. The study of two major famines in the 20th century supports a theory of medical genetics where multiple genetic mutations contribute to diseases.
A study by UCL scientists found that people's brains struggle to distinguish between real and imagined events, leading to hallucinations in schizophrenia. The researchers used fMRI scans to observe brain activity while participants remembered whether words had been seen or imagined.
Research on neuropeptide S suggests it can reduce biochemical and behavioral symptoms of schizophrenia, while also alleviating anxiety and promoting wakefulness. The study's findings indicate the NPS receptor could be a target for developing novel antipsychotic drugs.
Researchers discover altered activity in NRG1-erbB4 and NMDA receptor pairs, suggesting a relationship between the two and contributing to schizophrenia symptoms. The study's findings provide new insights into the molecular mechanisms underlying the disease.
A new theory suggests that two-thirds of people diagnosed with schizophrenia have suffered physical or sexual abuse, making it a major cause of the illness. The research argues that trauma, not just genetic predisposition, contributes to schizophrenic symptoms.
A study led by University of Iowa researchers found that people with schizophrenia struggle to understand body language, including facial expressions and non-verbal cues. Even those with mild symptoms and taking medication, they have difficulty extracting information from these socially relevant clues.
Researchers found that medication may delay the onset of psychosis in schizophrenia patients, leading to improved treatment outcomes and reduced symptoms. The study suggests that early recognition and treatment can help prevent or delay the development of full-blown psychosis in individuals with prodromal symptoms.
Dr. Andreasen, a leading expert on schizophrenia, receives Vanderbilt Prize for Biomedical Science for her groundbreaking research and mentorship of women in science. The award includes a $25,000 prize and establishes a scholarship to support a promising M.D./Ph.D. candidate.
Researchers found a specific pattern of DNA sequence variations in the dysbindin gene associated with impaired cognition and intelligence. The study suggests dysbindin influences variation in human cognitive ability, but only explains a small proportion, about 3 percent.
Researchers found that hospitalized patients with schizophrenia are more likely to experience serious infections, respiratory failure, and sepsis compared to those without the condition. The study suggests that improved quality of care could help mitigate this increased risk.
Researchers created a genetically altered mouse strain with overexpressed dopamine receptors in the striatum, which showed specific cognitive deficits similar to human schizophrenics. The study suggests that cognitive symptoms may arise from subtle genetic differences in the dopamine receptor gene.
Researchers created mice with a genetic defect that affects learning and memory, mirroring symptoms of schizophrenia. The animals struggled to adapt to new environments and scents, highlighting potential treatments for the mental health disorder.
A study of 1627 patients found that 53% stopped treatment early, with 36% citing ineffective treatment or worsening symptoms. Patients who experienced an early response to medication were 80% more likely to complete treatment, highlighting the importance of early symptom control and discussing treatment expectations.
A $1.75 million grant will establish the Australian Schizophrenia Research Bank, a nationally coordinated facility to support schizophrenia research. The bank will provide access to comprehensive, cross-referenced data on over 3,000 participants with schizophrenia and their families.
Studies using a laboratory model of PRODH deficiency demonstrate the role of COMT in compensating for overactive dopamine signaling, which contributes to schizophrenia symptoms. The findings show that disruptions in gene interaction, particularly between PRODH and COMT, play a crucial role in the development of schizophrenia.
Researchers found that repeated exposure to marijuana was related to abnormalities in the development of the arcuate fasciculus, a bundle of fibers connecting language and auditory functions. Longitudinal studies are needed to determine whether these changes in the brain are permanent or change over time.
Researchers have identified a new genetic link between PDE4B and DISC1 genes and mental illness, shedding light on the root causes of schizophrenia. The discovery suggests a potential new way of thinking about developing better treatments for this debilitating disease.
Researchers discovered sequence variations in the DISC1 gene that predict schizophrenia, neurocognitive deficits, and brain structure abnormalities. The study's findings offer hope for developing a treatment that can prevent or fix the protein's function.
Researchers at Penn have developed a new method using high-dimensional shape transformations to identify unique structural brain characteristics in schizophrenia patients. The study demonstrates the potential for early detection and prevention of the disease through MRI analysis.
The Schizophrenia Research Forum is a new online platform that aims to accelerate discovery by connecting researchers, experts, and clinicians. The site features interactive forums, live chats with leading scientists, and a searchable database of schizophrenia-related papers.
Researchers found 12 out of 15 participants with chronic schizophrenia made more accurate judgments than the best performer among a control group of non-schizophrenic volunteers. The study suggests that contextual processing may be less effective in schizophrenic brains, possibly due to insufficient inhibition.
A recent study contradicts earlier research suggesting that the neural development protein Oct-6 could be a marker for schizophrenia and bipolar disorder. Contrary to previous results, researchers found no difference in Oct-6 protein or mRNA expression between patients with these disorders and healthy individuals.
A Stanford study reveals that a single copy of the low-activity COMT protein may be a major risk factor for the development of schizophrenia or related psychotic disorders in children with a chromosome 22 deletion. This genetic variation can lead to an increased drop in verbal IQ, expressive language skills, and prefrontal cortex volume.